Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026
Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026
Company Drug

Lee’s Pharmaceutical’s Subsidiary Announces Positive Results for Myopia Treatment NVK002

Fineline Cube Oct 13, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...

Company Drug

J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials

Fineline Cube Oct 13, 2023

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...

Company Medical Device

Nanjing Geneseeq’s NSCLC TMB Detection Kit Approved by NMPA

Fineline Cube Oct 13, 2023

China-based Nanjing Geneseeq Medical Device and Diagnostic Inc. has announced that its tissue tumor mutation...

Company Drug

RemeGen Secures NMPA Approval for Phase II Study of Disitamab Vedotin in Breast Cancer

Fineline Cube Oct 13, 2023

China-based biopharma RemeGen Ltd (HKG: 9995) has announced that it has received approval from the...

Company Deals

Genetron Holdings Enters Privatization Agreement with Consortium

Fineline Cube Oct 13, 2023

Beijing-based Genetron Holdings Ltd (NASDAQ: GTH) has officially entered into a privatization and merger agreement...

Company Drug

Ascentage Pharma Initiates Phase III Study for APG-2575 and Calquence in CLL/SLL

Fineline Cube Oct 13, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) has announced the approval to commence a global multi-center, randomized,...

Company Drug

Betta Pharmaceuticals Secures NMPA Approval for Befotertinib in NSCLC Treatment

Fineline Cube Oct 13, 2023

China-based Betta Pharmaceuticals Co., Ltd. (SHE: 300558) has officially announced its receipt of market approval...

Company Drug

KPC Pharmaceuticals Secures WHO Prequalification for Dihydroartemisinin/Piperaquine

Fineline Cube Oct 13, 2023

Yunnan-based KPC Pharmaceuticals Inc. (SHA: 600422) has announced that its dihydroartemisinin/piperaquine 40mg/320mg formulation has received...

Company

Novartis Halts Phase II Clinical Study for MIJ821 in Major Depressive Disorder

Fineline Cube Oct 12, 2023

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has decided to hold the Phase II clinical...

Company Drug

MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Oct 12, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Bayer AG Plans Continued Investment in China Amidst Global Challenges

Fineline Cube Oct 12, 2023

Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as...

Company Drug

Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients

Fineline Cube Oct 12, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...

Company Deals

BMS Expands CAR-T Collaboration with Cellares on Automation Tech

Fineline Cube Oct 12, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares,...

Company Drug

Henlius Pharmaceutical Secures GMP Compliance for PD-1 Inhibitor Serplulimab in Indonesia

Fineline Cube Oct 12, 2023

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced that its partner, PT Kalbe Genexine...

Company Deals

Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates

Fineline Cube Oct 12, 2023

Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech...

Company Medical Device

Jiangsu BioPerfectus Secures NMPA Approval for Norovirus Nucleic Acid Detection Kit

Fineline Cube Oct 12, 2023

China-based Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading manufacturer of in vitro diagnostic...

Company

Kintor Pharmaceutical Secures NMPA Approval for Phase II Study of GT1708F in Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 12, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced that it has received approval from the...

Company Drug

Yiling Pharmaceutical Secures NMPA Approval for Phase I Study of G201-Na in Premenopausal Women

Fineline Cube Oct 12, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received approval from...

Company

Gritgen Therapeutics Commences Operations of Commercial GMP Facilities in Suzhou

Fineline Cube Oct 12, 2023

Suzhou-based gene therapy specialist, Gritgen Therapeutics Co., Ltd, has announced the validation completion and initiation...

Company Drug

GenFleet Therapeutics’ CDK9 Inhibitor SLS009 Earns Orphan Drug Status for AML

Fineline Cube Oct 12, 2023

Shanghai-based biotechnology company GenFleet Therapeutics has announced that its CDK9 inhibitor, SLS009 (GFH009), has received...

Posts pagination

1 … 454 455 456 … 659

Recent updates

  • Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
  • Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial
  • Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem
  • Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform
  • Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Company Medical Device

Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.